Durvalumab Monotherapy in Complex Advanced Hepatocellular Carcinoma: A Real‐World Study of Patients Ineligible for Combination Immunotherapy
Sign Up to like & getrecommendations! Published in 2025 at "Cancer Medicine"
DOI: 10.1002/cam4.70642
Abstract: Combination immunotherapy is the standard of care for advanced hepatocellular carcinoma (HCC). However, some patients are unsuitable for such treatment. This study investigated the safety and effectiveness of durvalumab monotherapy in a real‐world cohort with… read more here.
Keywords: durvalumab monotherapy; real world; advanced hepatocellular; hepatocellular carcinoma ... See more keywords
Combination of Immunotherapy and Photo‐pyroptosis as Novel Anticancer Strategy
Sign Up to like & getrecommendations! Published in 2022 at "ChemBioChem"
DOI: 10.1002/cbic.202200201
Abstract: Immunotherapy has made great progress in clinical cancer treatment in recent years, but its therapeutic efficacy is significantly limited by the lack of immunogenicity in the tumor microenvironment. Pyroptosis is a type of programmed cell… read more here.
Keywords: immunotherapy; pyroptosis; combination immunotherapy; photo pyroptosis ... See more keywords
Combination Immunotherapy for Type 1 Diabetes
Sign Up to like & getrecommendations! Published in 2017 at "Current Diabetes Reports"
DOI: 10.1007/s11892-017-0878-z
Abstract: Purpose of ReviewType 1 diabetes (T1D) is an autoimmune disease marked by β-cell destruction. Immunotherapies for T1D have been investigated since the 1980s and have focused on restoration of tolerance, T cell or B cell… read more here.
Keywords: combination immunotherapy; cell; insulin secretion; immunotherapy ... See more keywords
Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer
Sign Up to like & getrecommendations! Published in 2018 at "Cancer Cell"
DOI: 10.1016/j.ccell.2018.03.018
Abstract: Summary Combination immune checkpoint blockade has demonstrated promising benefit in lung cancer, but predictors of response to combination therapy are unknown. Using whole-exome sequencing to examine non-small-cell lung cancer (NSCLC) treated with PD-1 plus CTLA-4… read more here.
Keywords: combination; tmb; response; lung cancer ... See more keywords
Physical- and Chemical-Dually ROS-Responsive Nano-in-Gel Platforms with Sequential Release of OX40 Agonist and PD-1 Inhibitor for Augmented Combination Immunotherapy.
Sign Up to like & getrecommendations! Published in 2023 at "Nano letters"
DOI: 10.1021/acs.nanolett.2c04767
Abstract: Combination immunotherapy synergizing the PD-1 blockade with OX40 agonism has become a research hotspot, due to its enormous potential to overcome the restricted clinical objective response suffered by monotherapy. Questions of timing and sequence have… read more here.
Keywords: dually ros; combination immunotherapy; chemical dually; combination ... See more keywords
Nanohydroxyapatite Stimulates PD-L1 Expression to Boost Melanoma Combination Immunotherapy.
Sign Up to like & getrecommendations! Published in 2022 at "ACS nano"
DOI: 10.1021/acsnano.2c07818
Abstract: Although checkpoint-inhibitor immunotherapy held tremendous advances, improving immune response during treatment has always been an urgent clinical issue. With the help of mRNA microarray technology, it was found that short rod-like nanohydroxyapatite (nHA) promoted the… read more here.
Keywords: combination immunotherapy; nanohydroxyapatite stimulates; melanoma; immunotherapy ... See more keywords
Building on the anti-PD1/PD-L1 backbone: combination immunotherapy for cancer
Sign Up to like & getrecommendations! Published in 2019 at "Expert Opinion on Investigational Drugs"
DOI: 10.1080/13543784.2019.1649657
Abstract: ABSTRACT Introduction: Immunotherapy has revolutionized the treatment of cancer. Given this growing success, at the same time, there are significant limitations and unanswered questions concerning response rates, duration of therapy, why some patients respond and… read more here.
Keywords: anti pd1; immunotherapy; building anti; cancer ... See more keywords
Combination immunotherapy for pancreatic cancer: challenges and future considerations
Sign Up to like & getrecommendations! Published in 2022 at "Expert Review of Clinical Immunology"
DOI: 10.1080/1744666x.2022.2120471
Abstract: ABSTRACT Introduction Immune checkpoint inhibitors (ICI) have not yielded significant efficacy in pancreatic ductal adenocarcinoma (PDA), despite the role of the innate and adaptive immune systems on progression and survival. However, recently identified pathways have… read more here.
Keywords: immunotherapy pancreatic; combination immunotherapy; pancreatic cancer; challenges future ... See more keywords
IMMU-19. COMBINATION IMMUNOTHERAPY SEQUENCE MATTERS: VACCINE PRIOR TO ONCOLYTIC HSV VIROTHERAPY ENHANCES TUMOR-SPECIFIC T CELL RESPONSES AND EFFICACY
Sign Up to like & getrecommendations! Published in 2024 at "Neuro-Oncology"
DOI: 10.1093/neuonc/noae064.390
Abstract: Abstract BACKGROUND Safety and preliminary efficacy have been demonstrated with intratumoral oncolytic, engineered HSV immunotherapy; however, few responses have been durable, suggesting that augmented, prolonged anti-tumor T cell responses are likely required to maintain tumor… read more here.
Keywords: combination; combination immunotherapy; tumor; cell responses ... See more keywords
Distinct gut microbiota but common metabolomic signatures between viral and MASLD HCC contribute to outcomes of combination immunotherapy.
Sign Up to like & getrecommendations! Published in 2025 at "Hepatology"
DOI: 10.1097/hep.0000000000001446
Abstract: BACKGROUND AND AIMS Gut microbiota could modulate outcome of cancer immunotherapy including hepatocellular carcinoma (HCC). Although metabolic dysfunction-associated liver disease-related HCC (MASLD-HCC) and viral hepatitis-related HCC (V-HCC) exhibit different tumor microenvironments and gut microbiome composition,… read more here.
Keywords: gut microbiota; hcc; masld hcc; combination immunotherapy ... See more keywords
C‐PLAN index as a prognostic factor for patients with previously untreated advanced non‐small cell lung cancer who received combination immunotherapy: A multicenter retrospective study
Sign Up to like & getrecommendations! Published in 2023 at "Thoracic Cancer"
DOI: 10.1111/1759-7714.14798
Abstract: Combination immunotherapy (immune checkpoint inhibitors and cytotoxic anticancer agents) is widely used as first‐line treatment for advanced non‐small cell lung cancer (NSCLC). However, the therapeutic effect of combination immunotherapy has not been fully investigated. C‐reactive… read more here.
Keywords: combination immunotherapy; combination; advanced non; cancer ... See more keywords